NCT07223138
A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis
Enrolling by Invitation
PHASE3Ages 18+InterventionalTreatmentMoonLake Immunotherapeutics AG
~1,560 participants
Updated 2026-06-11 on ClinicalTrials.gov
What's tested:Sonelokimab
At a glance
Recruiting sites
0 of 16 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Long-term safety and tolerability of sonelokimab:
Measured over 52 weeks
+5 more outcomes measured
Conditions
Where it's being run
16 sites across 9 statesArizona4
Florida3
North Carolina2
Texas2
Arkansas1
California1
Ohio1
Pennsylvania1
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Long-term safety and tolerability of sonelokimab:52 weeks
Treatment-emergent adverse events (TEAEs)
- Long-term safety and tolerability of sonelokimab:52 weeks
Serious adverse events (SAEs)
- Long-term safety and tolerability of sonelokimab:52 weeks
TEAEs leading to study withdrawal
- Long-term safety and tolerability of sonelokimab:52 weeks
Adverse events of special interest (AESIs)
- Long-term safety and tolerability of sonelokimab:52 weeks
Clinically significant changes in vital signs and standard 12-lead electrocardiogram Measure description: Number of participants with clinically significant changes in vital signs and 12-lead ECG intervals from baseline
- Long-term safety and tolerability of sonelokimab:52 weeks
Clinically significant changes in clinical laboratory parameters Measure description: Number of participants with clinically significant changes in hematology, biochemistry and urinalysis from baseline